CAMBRIDGE, Mass. — Cellino has appointed Ed Tekeian as chief operating officer, tasking him with leading operations across engineering, platform development, and manufacturing as the company scales its personalized regenerative medicine platform.
The Cambridge-based regenerative medicine company said Tekeian will play a central role in advancing its automated biomanufacturing infrastructure, which is designed to enable scalable production of induced pluripotent stem cells (iPSCs) for use in personalized therapies.
Tekeian joined Cellino in 2024 as senior vice president of engineering, where he led the expansion of the company’s engineering organization and helped advance its autonomous manufacturing platform.
“Ed has been instrumental in helping scale our engineering organization and translating our technology vision into operational execution,” said Nabiha Saklayen, Ph.D., CEO and co-founder of Cellino. “As we continue building the infrastructure needed to make personalized regenerative medicine broadly accessible, Ed’s leadership will be critical to ensuring our platform can be deployed reliably and at scale.”
He brings more than 30 years of experience across hardware and software engineering, with a track record of leading multidisciplinary teams spanning mechanical, electrical, software, customer, and manufacturing functions. Over his career, Tekeian has contributed to multiple product launches across industries including 3D printing, dental medical devices, and radiosurgery technologies used in cancer treatment, helping drive the shipment of tens of thousands of commercial systems worldwide.
Before joining Cellino, Tekeian served as head of software at Formlabs, where he led teams developing user-facing software for advanced 3D printing systems. He previously held leadership roles as chief technology officer at Kuvée and Sample6 Technologies, and senior engineering positions at 3M Health Care, Brontes Technologies, and Zmed Inc. Brontes Technologies was later acquired by 3M, while Zmed was acquired by Varian Medical Systems.
“Cellino is bringing together powerful technologies to make patient-specific cells accessible to far more people,” said Tekeian. “I’m excited to help build the operational capabilities needed to scale this platform and support the development of regenerative therapies that could transform patient care.”
